| Business

Become a contributor

Bookmark Econotimes

| Business

Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil

Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring

American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns

Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge

Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances

Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies

Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning

Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units

Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO

Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit

Washington Post Publisher Will Lewis Steps Down After Layoffs

Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit

Anta Sports Expands Global Footprint With Strategic Puma Stake

American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing

Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push

DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins

©Econometrics LLC . All Rights Reserved.

Teligent, Inc. to Hold Conference Call for Fourth Quarter 2017 Results

Monday, March 12, 2018 8:30 PM UTC

BUENA, N.J., March 12, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Thursday March 15, 2018 to discuss the 4^th quarter 2017 financial results and business update.

The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to be joined into the Teligent, Inc. call.

This call is being webcast and can be accessed in the Investor Relations Section of Teligent, Inc.'s website at www.teligent.com.

About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring

Amazon Explores AI Content Marketplace With Media Publishers

Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion

Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units

U.S. Appeals Court Allows Trump Administration to End TPS for Honduras, Nepal, Nicaragua Migrants

U.S. Stock Futures Steady as Investors Await Key Jobs and Inflation Data

Russia Condemns U.S. Sanctions as Cuba Faces Critical Fuel Crisis

Hong Kong Leader Defends 20-Year Sentence for Jimmy Lai

India–US Trade Deal: Digital Tax Removal and $500 Billion Purchase Commitment Signal Major Policy Shift

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Teligent, Inc. to Hold Conference Call for Fourth Quarter 2017 Results

Editor's Picks

Welcome to EconoTimes